Search

One of the most contentious issues surrounding the forest conservation program REDD+ is the question whether it should be funded via international carbon markets. The controversy between market supporters and opponents has been especially marked in the public debate in Brazil, one of the main potential beneficiaries of REDD+ payments. In a remarkable shift of policy, the Brazilian Federal Government gave up its long-standing opposition to market-based funding in the run-up to the COP15, following several years of competition between two main discourse coalitions and their preferred story lines. These were analyzed here with discourse network analytical techniques. Brazil’s policy change may in part be explained by the failure of market opponents to employ positive arguments about alternative funding mechanisms, such as a public fund model; and by the increasing discursive dominance of a third emerging discourse coalition, which adopted major arguments of both sides in the debate. The research presented here thus provides more general insights on the dynamics of public debates, discourse coalitions, and the impacts of discursive strategies on policy-making, as well as on the value of discourse network analysis as a research method. Postprint

Many applications rely on time-intensive matrix operations, such as factorization, which can be sped up significantly for large sparse matrices by interpreting the matrix as a sparse graph and computing a node ordering that minimizes the so-called fill-in. In this paper, we engineer new data reduction rules for the minimum fill-in problem, which significantly reduce the size of the graph while producing an equivalent (or near-equivalent) instance. By applying both new and existing data reduction rules exhaustively before nested dissection, we obtain improved quality and at the same time large improvements in running time on a variety of instances. Our overall algorithm outperforms the state-of-the-art significantly: it not only yields better elimination orders, but it does so significantly faster than previously possible. For example, on road networks, where nested dissection algorithms are typically used as a preprocessing step for shortest path computations, our algorithms are on average six times faster than Metis while computing orderings with less fill-in.

Given a vertex-weighted graph, the maximum weight independent set problem asks for a pair-wise non-adjacent set of vertices such that the sum of their weights is maximum. The branch-and-reduce paradigm is the de facto standard approach to solve the problem to optimality in practice. In this paradigm, data reduction rules are applied to decrease the problem size. These data reduction rules ensure that given an optimum solution on the new (smaller) input, one can quickly construct an optimum solution on the original input. We introduce new generalized data reduction and transformation rules for the problem. A key feature of our work is that some transformation rules can increase the size of the input. Surprisingly, these so-called increasing transformations can simplify the problem and also open up the reduction space to yield even smaller irreducible graphs later throughout the algorithm. In experiments, our algorithm computes significantly smaller irreducible graphs on all except one instance, solves more instances to optimality than previously possible, is up to two orders of magnitude faster than the best state-of-the-art solver, and finds higher-quality solutions than heuristic solvers DynWVC and HILS on many instances. While the increasing transformations are only efficient enough for preprocessing at this time, we see this as a critical initial step towards a new branch-and-transform paradigm.

We perform a systematic study of the $��$-particle excitation from its ground state $0_1^+$ to the $0_2^+$ resonance. The so-called monopole transition form factor is investigated via an electron scattering experiment in a broad $Q^2$-range (from $0.5$ to $5.0$ fm$^{-2}$). The precision of the new data dramatically superseeds that of older sets of data, each covering only a portion of the $Q^2$-range. The new data allow the determination of two coefficients in a low-momentum expansion leading to a new puzzle. By confronting experiment to state-of-the-art theoretical calculations we observe that modern nuclear forces, including those derived within chiral effective field theory which are well tested on a variety of observables, fail to reproduce the excitation of the $��$-particle.

Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. Results: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial [CHEST-2]). Conclusion: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified. © 2020 The Authors